Asset profile
YN001
Protein / enzyme therapeutic
Evidence outlook · lead readout
NCT06048588 · Atherosclerotic Cardiovascular Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06048588: The study randomized 144 participants and used triple blinding with placebo and an active rosuvastatin comparator, but it was an early-phase dose-escalation study whose primary measures were safety and pharmacokinetics rather than a clinical outcome. Because no results are posted, whether any primary endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
July 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.